Study of Effect of Azeliragon in Patients Refractory to First-Line Metastatic Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This is an open label study to determine the safety and preliminary evidence of a therapeutic
effect of azeliragon in patients refractory to first-line or second-line treatment of
metastatic pancreatic cancer.